Navigation Links
Long-term Use of Antiepileptic Drug Vimpat® (Lacosamide) C-V Reduced Seizure Frequency and Severity and Improved Health-related Quality of Life Measures
Date:12/5/2011

a href="http://www.Vimpat.com">www.Vimpat.com or contact UCB at (800) 477-7877.

Vimpat® (C-V) is a Schedule V controlled substance.

Vimpat® is a registered trademark used under license from Harris FRC Corporation.

Important safety information about Vimpat® in the EU and EEA
Vimpat® is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 16 years and older. Lacosamide solution for infusion is an alternative for patients when oral administration is temporarily not feasible. Contraindications: Hypersensitivity to the active substance or any of the excipients; known second- or third-degree atrioventricular (AV) block. Special warnings and precautions for use: Treatment with lacosamide has been associated with dizziness which could increase the occurrence of accidental injury or falls. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medicine. Prolongations in PR interval with lacosamide have been observed in clinical studies. Cases with second- and third-degree AV block associated with lacosamide treatment have been reported in post-marketing experience. Lacosamide should be used with caution in patients with known conduction problems or severe cardiac disease such as a history of myocardial infarction or heart failure. Caution should especially be exerted when treating elderly patients as they may be at an increased risk of cardiac disorders or when lacosamide is used in combination with products known to be associated with PR prolongation. Second-degree or higher AV block has been reported in post-marketing experience. In the placebo-controlled trials of lacosamide in epilepsy patients, atrial fibrillation or flutter were not reported; however, both have been reported in open-label epilepsy trials and in post-marketing
'/>"/>

SOURCE UCB, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Three-Year Clinical Outcomes from Use of Genous™ Stent in Large, Real-World Patient Population Demonstrate Long-Term Safety and Efficacy
2. Merz research Shows Long-term Benefits for Patients With Dystonia
3. AdCare Health Systems Selects Remedi SeniorCare for Long-Term Care Pharmacy Solutions
4. Clinical Data Demonstrates Long-Term Safety of Boston Scientifics Alair[TM]Bronchial Thermoplasty System
5. Novus Scientific Announces the Worlds 1st Long-Term Absorbable Mesh as an Alternative to Non-Absorbable Synthetic Mesh
6. Rescheduled Webcast: Isis Pharmaceuticals Hosts Dr. John Kastelein to Review Mipomersen Long-term Data Recently Presented at ESC Congress 2011
7. Webcast Alert: Isis Pharmaceuticals Hosts Dr. John Kastelein to Review Mipomersen Long-term Data Recently Presented at ESC Congress 2011
8. NIH-Funded Study Demonstrates That Patients Receiving New CPR Devices (ResQPOD® and ResQPump™) and Cooling Have Improved Long-Term Brain Function Following Cardiac Arrest
9. Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion
10. Novocure Announces Long-Term Supply Agreement With ITT Corporation for Ceramic Sensor Technology
11. Analysis Compares Cost-Effectiveness of Premixed Insulin Analogs to Long-Acting Insulin Analogs in the Long-Term Treatment of Type 2 Diabetes in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 30, 2015  Astellas today announced topline results ... efficacy and safety of intravenous (IV) and oral ... development for adults with candidemia and other invasive ... demonstrated that the trial did not meet its ... in isavuconazole-treated patients at the end of IV ...
(Date:7/29/2015)... July 29, 2015 Insulet Corporation (NASDAQ: PODD ... its OmniPod ® Insulin Management System, today announced ... 30, 2015. The Company also announced that it will ... results and conference call from Thursday, July 30, as ... Revenue Highlights: , Preliminary second ...
(Date:7/29/2015)...  UBM Canon brings MEDevice San Diego Conference & ... on September 1-2, 2015, with a multi-track conference program ... Business Development track will be a panel on How ... featuring Renee Ryan , Vice President of Venture ... , Partner, Canaan Partners; and Jordan Kramer , ...
Breaking Medicine Technology:Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5Insulet Reports Preliminary Second Quarter 2015 Revenue Results 2Insulet Reports Preliminary Second Quarter 2015 Revenue Results 3Insulet Reports Preliminary Second Quarter 2015 Revenue Results 4Insulet Reports Preliminary Second Quarter 2015 Revenue Results 5MEDevice San Diego Offers Tips on Securing Financial Backing from Investors 2
... PXS; Nasdaq: PXSL) today announced that the company ... reached agreement on the phase 3,registration trial of ... The SPA process allows for FDA evaluation ... primary basis of an efficacy claim in support ...
... 19 The Australian company Fermiscan,who is using ... new breast cancer,screening test through the analysis of ... 69% in detecting breast cancer., (Photo: ... the Journal of the American Medical,Association(1) (US study), ...
Cached Medicine Technology:Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial 2Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial 3New Australian Technology: Detecting Breast Cancer With Hair 2New Australian Technology: Detecting Breast Cancer With Hair 3New Australian Technology: Detecting Breast Cancer With Hair 4
(Date:7/30/2015)... ... ... Bird B Gone, the leader in bird control products for commercial, industrial ... birds from the AC units and ventilation systems on hospital roofs. Bird droppings can ... Nile virus. When these droppings dry, the fine powder can be carried into hospitals ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... at multinational organizations and NGO’s, according to a new survey by leading international ... that property damage and employee medical expenses represented the largest sources of financial ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... After a ... Argus II retinal implant, more commonly known as the “bionic eye,” researchers have determined ... safe and viable tool for patients facing or already affected by complete vision loss ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... are living longer and do not find a complete removable denture acceptable. The ... of care. The practices that incorporate less expensive, immediate loading techniques will have ...
(Date:7/30/2015)... Orem, UT (PRWEB) , ... July 30, 2015 , ... When trying to gain weight, many people place a lot ... the amount of calories that need to be consumed. However, another key component to successful ... to gain weight. To assist with this, CB-1 Weight Gainer gives three tips on ...
Breaking Medicine News(10 mins):Health News:Bird B Gone’s New Bird Hazing System Keeps Disease-Carrying Bird Droppings Out of Hospitals 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2Health News:Chicago Implant Dentist/Implantologist Dr. Irfan Atcha Speaks to Local Dentists about Advances in Dental Implants in August. 2Health News:Chicago Implant Dentist/Implantologist Dr. Irfan Atcha Speaks to Local Dentists about Advances in Dental Implants in August. 3Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 2Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 3
... fatty acids may be unwise for those with weakened immunity.,Researchers ... for many years now and know that one of their ... - rich in omega-3s - often benefit those with arthritis, ... response is a key component of the immune system in ...
... the September 11 terrorist acts in New York and ... put on hold for several days, which severely affected ... are shipped via air due to their specific nature. ... pharmaceuticals with a radioactive component, and are used in ...
... study of middle-aged women suggests that those who eat the ... wide variety of foods. The Healthy Eating Index (HEI) is ... quality of someone's diet. This emphasises your eating pattern rather ... ten for servings of grains, vegetables, fruit, milk or meat, ...
... The balance of fats and oils in your diet can ... degeneration (AMD) is a currently untreatable disease of the eye ... suggests, it gets worse with age and diet has been ... Massachusetts Eye and Ear Infirmary carried out a study of ...
... not help the sickest patients, according to the latest ... the alveoli - are progressively destroyed, leaving the patient ... activities like climbing stairs or carrying their shopping. In ... surgery was beneficial for people with emphysema. It appeared ...
... The Food and Drug Administration has few details about ... are needed to protect both foreign patients taking experimental ... results. ,The number of pharmaceutical researchers working outside ... the FDA increased 16-fold from 1990 to 1999, dwarfing ...
Cached Medicine News:
... of any biological activity but appears to ... of insulin. Although insulin and C-Peptide are ... fasting levels of C-Peptide are 5-10 fold ... the longer half-life of C-Peptide. The glucagon ...
... The Array Multifocal IOL was designed ... with independence from glasses in most situations. ... IOL is similar to that of a ... usually much better and about 19 in ...
Inquire...
... IgG Enzymelinked Immunosorbent Assays(ELISA) is intended for ... antibody to Measles Rubeola) virus in human ... for the determination of immune status. Paired ... demonstrate seroconversion or a significant rise in ...
Medicine Products: